List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2835058/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharmaceutical Research, 1998, 15, 698-705.	3.5	796
2	Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. European Journal of Pharmaceutics and Biopharmaceutics, 2000, 50, 3-12.	4.3	588
3	Targeted delivery of nanoparticles for the treatment of lung diseases. Advanced Drug Delivery Reviews, 2008, 60, 863-875.	13.7	375
4	Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. International Journal of Pharmaceutics, 2004, 269, 457-467.	5.2	245
5	Current perspectives in dissolution testing of conventional and novel dosage forms. International Journal of Pharmaceutics, 2007, 328, 12-21.	5.2	218
6	Interaction of Poly(butylcyanoacrylate) Nanoparticles with the Blood-Brain Barrier <i>in vivo</i> and <i>in vitro</i> . Journal of Drug Targeting, 2001, 9, 209-221.	4.4	163
7	Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. Journal of Controlled Release, 2011, 150, 49-55.	9.9	154
8	Overview of the preparation of organic polymeric nanoparticles for drug delivery based on gelatine, chitosan, poly(d,l-lactide-co-glycolic acid) and polyalkylcyanoacrylate. Colloids and Surfaces B: Biointerfaces, 2014, 118, 154-163.	5.0	145
9	Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. International Journal of Pharmaceutics, 2006, 319, 155-161.	5.2	136
10	Biorelevant dissolution media as a predictive tool for glyburide a class II drug. European Journal of Pharmaceutical Sciences, 2006, 29, 45-52.	4.0	125
11	Liposomal Drug Delivery: A Versatile Platform for Challenging Clinical Applications. Journal of Pharmacy and Pharmaceutical Sciences, 2014, 17, 401.	2.1	120
12	Physicochemical Characterization of Solid Dispersions of Indomethacin with PEG 6000, Myrj 52, Lactose, Sorbitol, Dextrin, and Eudragit® E100. Drug Development and Industrial Pharmacy, 2004, 30, 303-317.	2.0	115
13	Computer simulations using GastroPlusâ,,¢ to justify a biowaiver for etoricoxib solid oral drug products. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 72, 91-98.	4.3	104
14	Dynamic Dissolution Testing To Establish In Vitro/In Vivo Correlations for Montelukast Sodium, a Poorly Soluble Drug. Pharmaceutical Research, 2008, 25, 2778-2785.	3.5	100
15	Nanoparticles: Characteristics, Mechanisms of Action, and Toxicity in Pulmonary Drug Delivery—A Review. Journal of Biomedical Nanotechnology, 2007, 3, 107-119.	1.1	99
16	Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. Journal of Controlled Release, 1998, 50, 21-30.	9.9	98
17	Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. Pharmaceutical Research, 2000, 17, 439-444.	3.5	92
18	Optimization of a two-step desolvation method for preparing gelatin nanoparticles and cell uptake studies in 143B osteosarcoma cancer cells. Journal of Pharmacy and Pharmaceutical Sciences, 2006, 9, 124-32	2.1	92

#	Article	IF	CITATIONS
19	Challenges and Future Prospects of Nanoemulsion as a Drug Delivery System. Current Pharmaceutical Design, 2017, 23, 495-508.	1.9	76
20	Uptake of PMMA nanoparticles from the gastrointestinal tract after oral administration to rats: modification of the body distribution after suspension in surfactant solutions and in oil vehicles. International Journal of Pharmaceutics, 1999, 176, 209-224.	5.2	71
21	Effervescent dry powder for respiratory drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 65, 346-353.	4.3	70
22	Evaluation of the DDSolver Software Applications. BioMed Research International, 2014, 2014, 1-9.	1.9	69
23	Evolution of Choice of Solubility and Dissolution Media After Two Decades of Biopharmaceutical Classification System. AAPS Journal, 2017, 19, 989-1001.	4.4	69
24	Body distribution of azidothymidine bound to nanoparticles after oral administration. European Journal of Pharmaceutics and Biopharmaceutics, 1997, 44, 127-132.	4.3	63
25	Niclosamide repositioning for treating cancer: Challenges and nano-based drug delivery opportunities. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 141, 58-69.	4.3	63
26	Macrophage Targeting of Azidothymidine: A Promising Strategy for AIDS Therapy*. AIDS Research and Human Retroviruses, 1996, 12, 1709-1715.	1.1	61
27	Promising nanotherapy in treating leishmaniasis. International Journal of Pharmaceutics, 2018, 547, 421-431.	5.2	59
28	<i>In Vitro</i> Release Kinetics of Antituberculosis Drugs from Nanoparticles Assessed Using a Modified Dissolution Apparatus. BioMed Research International, 2013, 2013, 1-9.	1.9	54
29	Evaluation of a microemulsion-based gel formulation for topical drug delivery of diclofenac sodium. Journal of Pharmaceutical Investigation, 2018, 48, 351-362.	5.3	50
30	Physicochemical characterization of five glyburide powders: A BCS based approach to predict oral absorption. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 1046-1056.	4.3	47
31	Mechanistic understanding of time-dependent oral absorption based on gastric motor activity in humans. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 313-325.	4.3	46
32	Pulmonary delivery of inhalable nanoparticles: dry powder inhalers. Therapeutic Delivery, 2011, 2, 1313-1324.	2.2	44
33	Provisional Biopharmaceutical Classification of Some Common Herbs Used in Western Medicine. Molecular Pharmaceutics, 2012, 9, 815-822.	4.6	44
34	A mini review of scientific and pharmacopeial requirements for the disintegration test. International Journal of Pharmaceutics, 2007, 345, 2-8.	5.2	41
35	Establishing the Pharmaceutical Quality of Chinese Herbal Medicine: A Provisional BCS Classification. Molecular Pharmaceutics, 2013, 10, 1623-1643.	4.6	41
36	Secondary cytotoxicity mediated by alveolar macrophages: A contribution to the total efficacy of nanoparticles in lung cancer therapy?. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 112-119.	4.3	37

#	Article	IF	CITATIONS
37	In-Vitro and In-Vivo Binding Activity of Chicken Egg Yolk Immunoglobulin Y (IgY) against Gliadin in Food Matrix. Journal of Agricultural and Food Chemistry, 2012, 60, 3166-3172.	5.2	35
38	Olive oil nanoemulsion preparation using high-pressure homogenization and d-phase emulsification – A design space approach. Journal of Drug Delivery Science and Technology, 2019, 49, 622-631.	3.0	35
39	Hyaluronic Acid-Tocopherol Succinate-Based Self-Assembling Micelles for Targeted Delivery of Rifampicin to Alveolar Macrophages. Journal of Biomedical Nanotechnology, 2015, 11, 1312-1329.	1.1	34
40	Simulated, biorelevant, clinically relevant or physiologically relevant dissolution media: The hidden role of bicarbonate buffer. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 142, 8-19.	4.3	34
41	Formulation and In Vivo Evaluation of Effervescent Inhalable Carrier Particles for Pulmonary Delivery of Nanoparticles. Drug Development and Industrial Pharmacy, 2008, 34, 943-947.	2.0	31
42	Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells. Acta Biomaterialia, 2018, 66, 294-309.	8.3	31
43	Cationic rifampicin nanoemulsion for the treatment of ocular tuberculosis. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2020, 597, 124755.	4.7	31
44	Buparvaquone Nanostructured Lipid Carrier: Development of an Affordable Delivery System for the Treatment of Leishmaniases. BioMed Research International, 2017, 2017, 1-11.	1.9	29
45	LC–MS/MS quantitation of phytocannabinoids and their metabolites in biological matrices. Talanta, 2019, 204, 846-867.	5.5	29
46	Cutting-edge advances in therapy for the posterior segment of the eye: Solid lipid nanoparticles and nanostructured lipid carriers. International Journal of Pharmaceutics, 2020, 589, 119831.	5.2	29
47	Pharmacokinetics of an immediate release, a controlled release and a two pulse dosage form in dogs. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 60, 17-23.	4.3	28
48	Pulmonary Toxicity of Polysorbate-80-coated Inhalable Nanoparticles; In vitro and In vivo Evaluation. AAPS Journal, 2010, 12, 294-299.	4.4	27
49	Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Enalapril. Journal of Pharmaceutical Sciences, 2017, 106, 1933-1943.	3.3	27
50	High internal vegetable oil nanoemulsion: D-phase emulsification as a unique low energy process. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2018, 554, 296-305.	4.7	27
51	Imparting bone mineral affinity to osteogenic proteins through heparin–bisphosphonate conjugates. Journal of Controlled Release, 2004, 98, 255-268.	9.9	26
52	Disease specific modeling: Simulation of the pharmacokinetics of meloxicam and ibuprofen in disease state vs. healthy conditions. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 100, 77-84.	4.3	26
53	Pharmacokinetic and Toxicodynamic Characterization of a Novel Doxorubicin Derivative. Pharmaceutics, 2017, 9, 35.	4.5	26
54	Biophysical Investigation of Nanoparticle Interactions with Lung Surfactant Model Systems. Journal of Biomedical Nanotechnology, 2006, 2, 245-252.	1.1	26

#	Article	IF	CITATIONS
55	Orally disintegrating dosage forms. Journal of Pharmaceutical Investigation, 2019, 49, 229-243.	5.3	25
56	Mechanistic evaluation of the effect of thermal-treating on Eudragit RS matrices. Il Farmaco, 2005, 60, 925-930.	0.9	24
57	Distribution of effervescent inhalable nanoparticles after pulmonary delivery: an <i>in vivo</i> study. Therapeutic Delivery, 2012, 3, 725-734.	2.2	24
58	Synergistic photoprotective activity of nanocarrier containing oil of Acrocomia aculeata (Jacq.) Lodd. Ex. Martius—Arecaceae. Industrial Crops and Products, 2018, 112, 305-312.	5.2	24
59	Gastric emptying and intestinal appearance of nonabsorbable drugs phenol red and paromomycin in human subjects: A multi-compartment stomach approach. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 129, 162-174.	4.3	24
60	The Significance of Disintegration Testing in Pharmaceutical Development. Dissolution Technologies, 2018, 25, 30-38.	0.6	24
61	Size Dependent Interactions of Nanoparticles with Lung Surfactant Model Systems and the Significant Impact on Surface Potential. Journal of Nanoscience and Nanotechnology, 2008, 8, 2971-2978.	0.9	23
62	Toward Global Standards for Comparator Pharmaceutical Products: Case Studies of Amoxicillin, Metronidazole, and Zidovudine in the Americas. AAPS Journal, 2012, 14, 462-472.	4.4	23
63	Physicochemical, in vitro and in vivo evaluation of flurbiprofen microemulsion. Anais Da Academia Brasileira De Ciencias, 2015, 87, 1823-1831.	0.8	23
64	Justification of disintegration testing beyond current FDA criteria using in vitro and in silico models. Drug Design, Development and Therapy, 2017, Volume11, 1163-1174.	4.3	23
65	Additive Polyplexes to Undertake siRNA Therapy against CDC20 and Survivin in Breast Cancer Cells. Biomacromolecules, 2018, 19, 4193-4206.	5.4	23
66	Advances in ophthalmic preparation: the role of drug nanocrystals and lipid-based nanosystems. Journal of Drug Targeting, 2020, 28, 259-270.	4.4	23
67	Simulation of In Vitro Dissolution Behavior Using DDDPlusâ, ,  AAPS PharmSciTech, 2015, 16, 217-221.	3.3	22
68	Targeting Leishmania amazonensis amastigotes through macrophage internalisation of a hydroxymethylnitrofurazone nanostructured polymeric system. International Journal of Antimicrobial Agents, 2017, 50, 88-92.	2.5	21
69	Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans—Part 1: Fasted State Conditions. Molecular Pharmaceutics, 2018, 15, 5454-5467.	4.6	21
70	Anti-inflammatory drug nanocrystals: state of art and regulatory perspective. European Journal of Pharmaceutical Sciences, 2021, 158, 105654.	4.0	21
71	Development of a novel cannabinoid-loaded microemulsion towards an improved stability and transdermal delivery. International Journal of Pharmaceutics, 2021, 604, 120766.	5.2	21
72	Impact of Tether Length on Bone Mineral Affinity of Protein-Bisphosphonate Conjugates. Pharmaceutical Research, 2004, 21, 608-616.	3.5	20

#	Article	IF	CITATIONS
73	In Vitro Dissolution of Generic Immediate-Release Solid Oral Dosage Forms Containing BCS Class I Drugs: Comparative Assessment of Metronidazole, Zidovudine, and Amoxicillin Versus Relevant Comparator Pharmaceutical Products in South Africa and India. AAPS PharmSciTech, 2014, 15, 1076-1086.	3.3	20
74	Multiple siRNA delivery against cell cycle and anti-apoptosis proteins using lipid-substituted polyethylenimine in triple-negative breast cancer and nonmalignant cells. Journal of Biomedical Materials Research - Part A, 2016, 104, 3031-3044.	4.0	20
75	The Irrelevance of InÂVitro Dissolution in Setting Product Specifications for Drugs Like Dextromethorphan That are Subject to Lysosomal Trapping. Journal of Pharmaceutical Sciences, 2019, 108, 268-278.	3.3	20
76	Development of a bladder instillation of the indoloquinone anticancer agent EO-9 using tert-butyl alcohol as lyophilization vehicle. AAPS PharmSciTech, 2007, 8, E78-E87.	3.3	19
77	Measuring the Impact of Gastrointestinal Variables on the Systemic Outcome of Two Suspensions of Posaconazole by a PBPK Model. AAPS Journal, 2018, 20, 57.	4.4	19
78	Nano-sized Droplets of Self-Emulsifying System for Enhancing Oral Bioavailability of Chemotherapeutic Agent VP-16 in Rats: A Nano Lipid Carrier for BCS Class IV Drugs. Journal of Pharmacy and Pharmaceutical Sciences, 2018, 21, 398-408.	2.1	17
79	Raman Spectroscopy for Quantitative Analysis in the Pharmaceutical Industry. Journal of Pharmacy and Pharmaceutical Sciences, 2020, 23, 24-46.	2.1	17
80	Investigation of the Performance of the Disintegration Test for Dietary Supplements. AAPS Journal, 2010, 12, 602-607.	4.4	15
81	Production and characterization of antibodies against crosslinked gelatin nanoparticles and first steps toward developing an ELISA screening kit. Analytical and Bioanalytical Chemistry, 2012, 403, 2851-2857.	3.7	15
82	Antiulcerogenic Potential Activity of Free and NanoencapsulatedPassiflora serratodigitataL. Extracts. BioMed Research International, 2014, 2014, 1-7.	1.9	15
83	In Silico Prediction of Plasma Concentrations of Fluconazole Capsules with Different Dissolution Profiles and Bioequivalence Study Using Population Simulation. Pharmaceutics, 2019, 11, 215.	4.5	15
84	Phytocannabinoid drug-drug interactions and their clinical implications. , 2020, 215, 107621.		15
85	Fatty acid chain length impacts nanonizing capacity of albumin-fatty acid nanomicelles: Enhanced physicochemical property and cellular delivery of poorly water-soluble drug. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 152, 257-269.	4.3	15
86	Real-Time Imaging of Interactions Between Dipalmitoylphosphatidylcholine Monolayers and Gelatin Based Nanoparticles Using Brewster Angle Microscopy. Journal of Biomedical Nanotechnology, 2010, 6, 145-152.	1.1	15
87	A Method for the Analysis of Ginsenosides, Malonyl Ginsenosides, and Hydrolyzed Ginsenosides Using High-Performance Liquid Chromatography with Ultraviolet and PositiveMode Electrospray IonizationMass Spectrometric Detection. Journal of AOAC INTERNATIONAL, 2006, 89, 16-21.	1.5	14
88	Co-delivery of buparvaquone and polymyxin B in a nanostructured lipid carrier for leishmaniasis treatment. Journal of Global Antimicrobial Resistance, 2019, 18, 279-283.	2.2	14
89	Highly Water-Soluble Orotic Acid Nanocrystals Produced by High-Energy Milling. Journal of Pharmaceutical Sciences, 2019, 108, 1848-1856.	3.3	14
90	Antibiotic-loaded lipid-based nanocarrier: A promising strategy to overcome bacterial infection. International Journal of Pharmaceutics, 2022, 621, 121782.	5.2	14

#	Article	IF	CITATIONS
91	Design Space Approach for Preservative System Optimization of an Anti-Aging Eye Fluid Emulsion. Journal of Pharmacy and Pharmaceutical Sciences, 2015, 18, 551.	2.1	13
92	Design space approach in the development of esculetin nanocrystals by a small-scale wet-bead milling process. Journal of Drug Delivery Science and Technology, 2020, 55, 101486.	3.0	13
93	Enhanced In Vitro Antimicrobial Activity of Polymyxin B–Coated Nanostructured Lipid Carrier Containing Dexamethasone Acetate. Journal of Pharmaceutical Innovation, 2021, 16, 125-135.	2.4	13
94	Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans—Part 2: Fed State. Molecular Pharmaceutics, 2018, 15, 5468-5478.	4.6	12
95	Importance of the fatty acid chain length on in vitro and in vivo anticancer activity of fattigation-platform albumin nanoparticles in human colorectal cancer xenograft mice model. Journal of Controlled Release, 2020, 324, 55-68.	9.9	12
96	Rifampicin nanocrystals: Towards an innovative approach to treat tuberculosis. Materials Science and Engineering C, 2020, 112, 110895.	7.3	12
97	Enhancement of the intestinal absorption of bortezomib by self-nanoemulsifying drug delivery system. Pharmaceutical Development and Technology, 2020, 25, 351-358.	2.4	11
98	Revolutionizing polymer-based nanoparticle-linked vaccines for targeting respiratory viruses: A perspective. Life Sciences, 2021, 280, 119744.	4.3	11
99	Rational design of oral flubendazole-loaded nanoemulsion for brain delivery in cryptococcosis. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2021, 630, 127631.	4.7	11
100	Investigation of the Disintegration Behavior of Dietary Supplements in Different Beverages. Dissolution Technologies, 2013, 20, 6-9.	0.6	11
101	Brush border membrane vesicle and Caco-2 cell line: Two experimental models for evaluation of absorption enhancing effects of saponins, bile salts, and some synthetic surfactants. Journal of Advanced Pharmaceutical Technology and Research, 2016, 7, 75.	1.0	11
102	Mechanistic understanding of underperforming enteric coated products: Opportunities to add clinical relevance to the dissolution test. Journal of Controlled Release, 2020, 325, 323-334.	9.9	10
103	Immune response to antituberculosis drug-loaded gelatin and polyisobutyl-cyanoacrylate nanoparticles in macrophages. Therapeutic Delivery, 2016, 7, 213-228.	2.2	9
104	Are the release characteristics of Erzhi pills in line with traditional Chinese medicine theory? A quantitative study. Journal of Integrative Medicine, 2021, 19, 50-55.	3.1	9
105	Influence of the Changed USP Specifications on Disintegration Test Performance. Dissolution Technologies, 2010, 17, 6-10.	0.6	9
106	A new medium-throughput screening design approach for the development of hydroxymethylnitrofurazone (NFOH) nanostructured lipid carrier for treating leishmaniasis. Colloids and Surfaces B: Biointerfaces, 2020, 193, 111097.	5.0	9
107	Vaping additives negatively impact the stability and lateral film organization of lung surfactant model systems. Nanomedicine, 2022, 17, 827-843.	3.3	9
108	Physical–chemical properties of furosemide nanocrystals developed using rotation revolution mixer. Pharmaceutical Development and Technology, 2016, 21, 812-822.	2.4	8

#	Article	IF	CITATIONS
109	Mechanistic understanding of the effect of renal impairment on metformin oral absorption using computer simulations. Journal of Pharmaceutical Investigation, 2017, 47, 151-161.	5.3	8
110	Erding Formula in hyperuricaemia treatment: unfolding traditional Chinese herbal compatibility using modern pharmaceutical approaches. Journal of Pharmacy and Pharmacology, 2017, 70, 124-132.	2.4	8
111	Biphasic Dissolution as an Exploratory Method during Early Drug Product Development. Pharmaceutics, 2020, 12, 420.	4.5	8
112	Oral delivery of solid lipid nanoparticles: underlining the physicochemical characteristics and physiological condition affecting the lipolysis rate. Expert Opinion on Drug Delivery, 2021, 18, 1707-1722.	5.0	8
113	Investigating the Dissolution Profiles of Amoxicillin, Metronidazole, and Zidovudine Formulations used in Trinidad and Tobago, West Indies. AAPS PharmSciTech, 2014, 15, 1060-1069.	3.3	7
114	Inflammation Caused by Nanosized Delivery Systems: Is There a Benefit?. Molecular Pharmaceutics, 2016, 13, 3270-3278.	4.6	7
115	Application of in Silico Tools in Clinical Practice using Ketoconazole as a Model Drug. Journal of Pharmacy and Pharmaceutical Sciences, 2018, 21, 242s-253s.	2.1	7
116	"Development of Fixed Dose Combination Products―Workshop Report: Considerations of Gastrointestinal Physiology and Overall Development Strategy. AAPS Journal, 2019, 21, 75.	4.4	7
117	Cancer treatment in the lymphatic system: A prospective targeting employing nanostructured systems. International Journal of Pharmaceutics, 2020, 587, 119697.	5.2	7
118	Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics. Journal of Microencapsulation, 2021, 38, 192-202.	2.8	7
119	Traditional Chinese Medicine "Pillâ€; an Ancient Dosage Form with Surprising Modern Pharmaceutical Characteristics. Pharmaceutical Research, 2021, 38, 199-211.	3.5	7
120	Applications and practice of advanced drug delivery systems for targeting Toll-like receptors in pulmonary diseases. Nanomedicine, 2021, 16, 783-786.	3.3	7
121	Advanced drug delivery systems targeting NF-κB in respiratory diseases. Future Medicinal Chemistry, 2021, 13, 1087-1090.	2.3	7
122	Comparing the Dissolution Profiles of Seven Metformin Formulations in Simulated Intestinal Fluid. Dissolution Technologies, 2015, 22, 17-21.	0.6	7
123	The Lymphatic System: A Sometimes-Forgotten Compartment in Pharmaceutical Sciences. Journal of Pharmacy and Pharmaceutical Sciences, 2021, 24, 533-547.	2.1	7
124	Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum. European Journal of Pharmaceutical Sciences, 2022, 169, 106097.	4.0	7
125	Promoting antigen escape from dendritic cell endosomes potentiates anti-tumoral immunity. Cell Reports Medicine, 2022, 3, 100534.	6.5	7
126	Microcalorimetric Method to Assess Phagocytosis: Macrophage-Nanoparticle Interactions. AAPS Journal, 2011, 13, 20-29.	4.4	6

#	Article	IF	CITATIONS
127	An Algorithm to Identify Compounded Non-Sterile Products that Can Be Formulated on a Commercial Scale or Imported to Promote Safer Medication Use in Children. Pharmacy (Basel, Switzerland), 2015, 3, 284-294.	1.6	6
128	Fabrication and <i>in vitro</i> characterization of gadolinium-based nanoclusters for simultaneous drug delivery and radiation enhancement. Nanotechnology, 2016, 27, 385104.	2.6	6
129	Intrinsic dissolution simulation of highly and poorly soluble drugs for BCS solubility classification. Dissolution Technologies, 2017, 24, 6-11.	0.6	6
130	Challenges and Opportunities to Use Biowaivers to Compare Generics in China. AAPS PharmSciTech, 2014, 15, 1070-1075.	3.3	5
131	Reverse phase high-performance liquid chromatography for quantification of hydroxymethylnitrofurazone in polymeric nanoparticles. Brazilian Journal of Pharmaceutical Sciences, 2015, 51, 561-567.	1.2	5
132	The critical role of NIR spectroscopy and statistical process control (SPC) strategy towards captopril tablets (25 mg) manufacturing process understanding: a case study. Pharmaceutical Development and Technology, 2015, 20, 345-351.	2.4	5
133	In silico Tools at Early Stage of Pharmaceutical Development: Data Needs and Software Capabilities. AAPS PharmSciTech, 2019, 20, 243.	3.3	5
134	Drug delivery advances in mitigating inflammation via matrix metalloproteinases in respiratory diseases. Nanomedicine, 2021, 16, 437-439.	3.3	5
135	Evaluation of the Rupture Test for Stability Studies of Soft-Shell Capsules. Dissolution Technologies, 2017, 24, 16-19.	0.6	5
136	In Silico Simulation of Dissolution Profiles for Development of Extended-Release Doxazosin Tablets. Dissolution Technologies, 2018, 25, 14-21.	0.6	5
137	Investigations of the antipyretic effect and safety of Prasachandaeng, a traditional remedy from Thailand national list of essential medicines. Biomedicine and Pharmacotherapy, 2022, 147, 112673.	5.6	5
138	Investigation of vitamin and mineral tablets and capsules on the Canadian market. Journal of Pharmacy and Pharmaceutical Sciences, 2006, 9, 40-9.	2.1	5
139	Activation of a photosensitive pharmaceutical agent by a triboluminescent material. Applied Physics Letters, 2006, 88, 123901.	3.3	4
140	Transdermal drug delivery: feasibility for treatment of superficial bone stress fractures. Drug Delivery and Translational Research, 2015, 5, 540-551.	5.8	4
141	Compounded Nonsterile Preparations and FDA-Approved Commercially Available Liquid Products for Children: A North American Update. Pharmaceutics, 2022, 14, 1032.	4.5	4
142	Biomedical Applications of polymeric micelles in the treatment of diabetes mellitus: Current success and future approaches. Expert Opinion on Drug Delivery, 2022, 19, 771-793.	5.0	4
143	The effect of compression forces on the stability of dibasic calcium phosphate dihydrate tablets in the presence of glutamic acid hydrochloride monitored by isothermal calorimetry. Thermochimica Acta, 2008, 467, 86-90.	2.7	3
144	Development of an ultrasensitive hetero-sandwich ELISA assay based on bispecific monoclonal antibody for the detection of dengue NS1 protein. Journal of Pharmacy Research, 2013, 7, 374-380.	0.4	3

#	Article	IF	CITATIONS
145	Development of an algorithm to identify mass production candidate molecules to develop children's oral medicines: a North American perspective. AAPS Open, 2016, 2, .	1.3	3
146	N,N,N-trimethylchitosan-poly (n-butylcyanoacrylate) core-shell nanoparticles as a potential oral delivery system for acyclovir. Colloids and Surfaces B: Biointerfaces, 2020, 196, 111336.	5.0	3
147	Physiologically relevant dissolution conditions towards improved in vitro - in vivo relationship – A case study with enteric coated pantoprazole tablets. International Journal of Pharmaceutics, 2021, 605, 120857.	5.2	3
148	Esculetin as bioactive marker: towards a rational scientific approach for the treatment of hyperuricemia using Traditional Chinese Medicine. Brazilian Journal of Pharmaceutical Sciences, 0, 56,	1.2	3
149	Crystal-liquid Fugacity Ratio as a Surrogate Parameter for Intestinal Permeability. Journal of Pharmacy and Pharmaceutical Sciences, 2016, 19, 312.	2.1	2
150	In Vitro Evaluation of a Foamable Microemulsion Towards an Improved Topical Delivery of Diclofenac Sodium. AAPS PharmSciTech, 2022, 23, 102.	3.3	2
151	Using GastroPlus to teach complex biopharmaceutical concepts. Pharmacy Education, 2022, 22, 336-347.	0.6	2
152	Special focus issue on targeted drug delivery for inflammatory lung diseases. Nanomedicine, 2022, 17, 813-815.	3.3	2
153	Isothermal Microcalorimetry as a Quality by Design Tool to Determine Optimal Blending Sequences. AAPS Journal, 2010, 12, 417-423.	4.4	1
154	What Western Pharmacists Need to Know About Traditional Chinese Medicine; A Canadian Perspective. Current Traditional Medicine, 2015, 1, 18-25.	0.4	1
155	Traditional Chinese Medicine for Managing Inflammatory Pain of Arthritis with Herbal Medicines. Current Traditional Medicine, 2016, 2, 80-93.	0.4	1
156	Effects of self-assembled cell-penetrating peptides and their nano-complexes on ABCB1 expression and activity. Iranian Journal of Basic Medical Sciences, 2021, 24, 383-390.	1.0	0
157	A BCS-Based Biowaiver Approach Using Biphasic Dissolution Test. Dissolution Technologies, 2021, 28, 40-48.	0.6	Ο
158	Interaction of M2 macrophages with hepatocellular carcinoma co-culture system in the presence of doxorubicin-loaded nanoparticles. Journal of Drug Delivery Science and Technology, 2022, , 103487.	3.0	0